FLT3 mutations in myeloid sarcoma

M. Ali Ansari-Lari, Ching Fen Yang, Rima Tinawi-Aljundi, Lisa Cooper, Patricia Long, Robert H. Allan, Michael J. Borowitz, Karin D. Berg, Kathleen M. Murphy

Research output: Contribution to journalArticlepeer-review


Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms-like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20-40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas-containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.

Original languageEnglish (US)
Pages (from-to)785-791
Number of pages7
JournalBritish journal of haematology
Issue number6
StatePublished - Sep 2004


  • Acute myeloid leukaemia
  • FLT3
  • Molecular pathology
  • Mutation
  • Myeloid sarcoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'FLT3 mutations in myeloid sarcoma'. Together they form a unique fingerprint.

Cite this